References

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8-29.

2. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801-818.

3. Lynch HT, de la Chapelle A. Genomic medicine: hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932.

4. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677-685.

5. Lynch HT, Lynch J, Conway T, Watson P, Coleman RL. Familial aggregation of carcinoma of the endometrium. Am J Obstet Gynecol 1994; 171: 24-27.

6. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 2003; 21: 740-753.

7. Lynch HT, Cavalieri RJ, Lynch JF, Casey MJ. Gynecologic cancer clues to Lynch syndrome II diagnosis: a family report. Gynecol Oncol 1992; 44: 198-203.

8. Shannon C, Kirk J, Barnetson R, et al. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res 2003; 9: 1387-1392.

9. Chung L, Broaddus R, Crozier M, Luthraa R, Levenback C, Lu K. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 2003; 102: 1152-1155.

10. Mutter GE. Molecular pathogenesis of endometrial cancer. International Society of Gynecologic Pathologists, Companion Meeting Syllabus. Annual meeting of the United States and Canadian Academy of Pathologists; 2003 March 22-28; Washington, DC. United States and Canadian Academy of Pathologists 2003, pp. 59-72.

11. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol 2001; 158: 1895-1898.

12. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.

13. Way SA. The aetiology of carcinoma of the body of the uterus. J Obstet Gynaecol Br Comm 1954; 61: 46-58.

14. Murphy DP. Heredity in Uterine Cancer. Cambridge MA: Harvard University Press, 1952.

15. Ivanovich J, Babb S, Goodfellow P, et al. Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 2002; 8: 1849-1856.

16. Nyholm HCJ, Nielsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: Comparison of clinical and histopathological characteristics. Gynecol Oncol 1993; 49: 229-235.

17. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II:

Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 1990; 94: 255-260.

18. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993; 50: 281-286.

19. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13: 295-308.

20. Sherman ME, Kurman RJ. Evolving concepts in endometrial carcinogenesis: importance of DNA repair and deregulated growth. Hum Pathol 1998; 29: 1035-1038.

21. McCluggage WG. Immunohistochemistry of endometrial cancer. International Society of Gynecologic Pathologists, Companion Meeting Syllabus. Annual meeting of the United States and Canadian Academy of Pathologists; 2003 March 22-28; Washington, DC. United States and Canadian Academy of Pathologists 2003, pp. 49-58.

22. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002; 117: 541-545.

22a. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. (Mechanisms of Disease). N Engl J Med 2003; 349: 2042-2054.

23. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Chapter 12, in Blaustein's Pathology of the Female Genital Tract (Kurman RJ, ed.), New York, NY: Springer-Verlag Publishers, 2002, pp. 501-536.

23a. van den Bos M, van den Hoven M, Jonhegan E, et al. More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon. Am J Surg Pathol 2004; 28: 706-711.

24. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000; 85: 2334-2338.

25. Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol 2000; 19: 301-309.

26. Mutter GL. Endometrium.org. Brigham and Women's Hospital, Harvard Medical School. Available at: URL:http://www.endometrium.org. Accessed August 16, 2004.

27. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002; 15: 1032-1037.

28. Nilbert M, Gronberg H, Lindblom A. Essential to discover hereditary colorectal and endometrial cancer. Mutations in "HNPCC individuals" can cause several different tumors. Lakartidningen 2002; 99: 3296-3300.

29. Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues. Am J Clin Pathol 2000; 113: 576-582.

30. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413-2417.

31. Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer 1997; 18: 219-227.

32. de Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000; 192: 328-335.

33. Catasus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998; 29: 1160-1164.

34. Ichikawa Y, Lemon SJ, Wang S, et al. Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet 1999; 112: 2-8.

35. Berends MJW, Hollema H, Wu Y, et al. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer 2001; 92: 398-403.

36. Parc YR, Halling KC, Burgart LJ, et al. Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. Int J Cancer 2000; 86: 60-66.

37. Planck M, Rambech E, Moslein G, Muller W, Olsson H, Nilbert M. High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer 2002; 94: 2502-2510.

38. Schwartz S Jr, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999; 59: 2995-3002.

39. Cederquist K, Emanuelsson M, Goransson I, et al. Mutation analysis of the MLH1, MSh2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in Northern Sweden. Int J Cancer 2004; 109: 370-376.

40. Hendriks YMC, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127: 17-25.

41. Kuismanen SA, Moisio AL, Schweizer P, et al. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 2002; 160: 1953-1958.

42. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R. CYP1B1 gene in endometrial cancer. Mol Cell Endocrinol 2003; 202: 171-176.

43. Sasaki M, Sakuragi N, Dahiya R. The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun 2003; 305: 1105-1108.

44. Vasen HFA, Watson P, Mecklin J-P, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994; 14: 1675-1678.

45. Brown GJ, St. John DJ, Macrae FA, Aittomaki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001; 80: 346-349.

46. Creasman W, Odincino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 1998; 3: 35-61.

47. Demographic Analysis Section DoCCaPNCI. Surveillance, epidemiology, and end results: incidence and mortality data, 1973-1977 (Young JL Jr, Percy CL, Asire AJ ed.). NIH Publication No. 81-2330, 1981, 66-88. Bethesda, Maryland, US. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute. National Cancer Institute Monograph 57.

48. Hemminki K, Vaittinen P, Dong C. Endometrial cancer in the Family-Cancer Database. Cancer Epidemiol Biomarkers Prev 1999; 8: 1005-1010.

49. Hemminki K, Granstrom C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer 2004; 40: 90-95.

50. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82: 223-228.

51. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Sem Surg Oncol 1994; 10: 31-46.

52. Pecorelli S, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 1998; 3: 75-102.

53. Schildkraut JM, Thompson WD. Relationship of epithelial ovarian cancer to other malignancies within families. Genet Epidemiol 1988; 5: 355-367.

54. Hakala T, Mecklin JP, Forss M, Jarvinen H, Lehtovirta P. Endometrial carcinoma in the cancer family syndrome. Cancer 1991; 68: 1656-1659.

55. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430-433.

56. Millar AL, Pal T, Madlensky L, et al. Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 1999; 8: 823-829.

57. Weinberg DS, Newschaffer CJ, Topham A. Risk for colorectal cancer after gynecologic cancer. Ann Intern Med 1999; 131: 189-193.

58. Pal T, Flanders T, Mitchell-Lehman M, et al. Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 1998; 35: 978-984.

59. Vasen HFA, Offerhaus GJA, Den Hartog Jager FCA, et al. The tumor spectrum in hereditary nonpolyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 1990; 46: 31-34.

60. Vasen HFA, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-1027.

61. Wijnen JT, Vasen HFA, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998; 339: 511-518.

62. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-218.

63. Cederquist K, Golovleva I, Emanuelsson M, Stenling R, Grönberg H. A population-based cohort study of patients with multiple colon and endometrial cancer: correlation of microsatellite instability (MSI) status, age at diagnosis and cancer risk. Int J Cancer 2001; 91: 486-491.

64. Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 793-798.

65. Maruyama A, Saito T, Hachitanda Y, Tsukamoto N. Cancer history and loss of MSH2 and MSH1 protein expression in patients with endometrial hyperplasia. Int J Gynecol Cancer 2003; 13: 352-360.

66. Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 2003; 22: 141-148.

67. Sutter C, Dallenbach-Helweg G, Schmidt D, et al. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma. Int J Gynecol Pathol 2004; 23: 18-25.

68. Watson P, Vasen HFA, Mecklin J-P, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516-520.

69. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. JAMA 1997; 277: 915-919.

70. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91: 74-80.

71. Casey MJ, Bewtra C, Garcia-Padial J, Lynch HT. Laparoscopic examination and assisted bilateral salpingo-oophorectomy hysterectomy for prophylactic removal of the ovaries and uterus in women at genetic risk for ovarian cancer. J Gynecol Tech 1995; 1: 111-114.

72. Lynch HT, Watson P, Shaw TG, et al. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: hereditary nonpolyposis colorectal carcinoma as a model. Cancer 1999; 86: 2457-2463.

73. Lynch HT, Riley BD, Weismann S, et al. Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 2004; 100: 53-64.

74. Casey MJ, Garcia-Padial J, Johnson C, Osborne NG, Sotolongo J, Watson P. A critical analysis of laparoscopic assisted vaginal hysterectomies compared with vaginal hysterectomies unassisted by laparoscopy and transabdominal hysterectomies. J Gynecol Surg 1994; 10: 7-14.

75. Casey MJ, Garcia-Padial J, Hakert D, Watson P. Changing trends in surgical approaches to hysterectomy: an analysis of the use of laparoscopic assisted vaginal hysterectomies in clinic practice. J Gynecol Surg 1988; 14: 15-24.

76. Garcia-Padial J, Sotolongo J, Casey MJ, Johnson C, Osborne NG. Laparoscopy-assisted vaginal hysterectomy: report of seventy-five consecutive cases. J Gynecol Surg 1992; 8: 81-85.

77. Lynch HT, Krush AJ, Larsen AL, Magnuson cW. Endometrial carcinoma: multiple primary malignancies, constitutional factors, and heredity. Am J Med Sci 1966; 252: 381-390.

78. Lynch HT, Krush AJ, Larsen AL. Heredity and endometrial carcinoma. Southern Med J 1967; 60(3): 231-235.

79. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966; 19: 489-520.

80. Stewart HL, Dunham LJ, Casper J, et al. Epidemiology of cancers of the uterine cervix and corpus, breast and ovary in Israel and New York City. J Natl Cancer Inst 1966; 37: 1-95.

81. Baanders-vanHalewijn EA, de Waard F, Mastboom JL, Tonkes E, Meinsma L. Constitutional and hereditary aspects of endometrial cancer. Z Geburtshilfe Gynakol 1963; 161: 77-93.

82. Brobeck 0. Heredity in Cancer Uteri: A Genetical and Clinical Study of 200 Patients with Cancer of the Cervix Uteri and 90 Patients with Cancer of the Corpus Uteri. Aarhus, Denmark: Universitetsfarlaget, 1949.

83. Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer 1961; 14: 231-237.

84. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966; 117: 206-212.

85. Dockerty MB, Jackson RL. The Stein-Levinthal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 1957; 73: 161-173.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment